Related references
Note: Only part of the references are listed.Deletion of fibroblast activation protein provides atheroprotection
Sokrates Stein et al.
CARDIOVASCULAR RESEARCH (2021)
A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis
Qi Pan et al.
EBIOMEDICINE (2021)
Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor
Hui Jin Jung et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
Circulating FGF21 Levels in Human Health and Metabolic Disease
Michaela Keuper et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2020)
Fibroblast Activation Protein is a GH Target: A Prospective Study of Patients with Acromegaly Before and After Treatment
Mai C. Arlien-Soborg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Discovery of a novel fibroblast activation protein (FAP) inhibitor, BR103354, with anti-diabetic and anti-steatotic effects
Jae Min Cho et al.
SCIENTIFIC REPORTS (2020)
AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients
Allegra Kaufman et al.
CELL REPORTS MEDICINE (2020)
Identification of Novel Natural Substrates of Fibroblast Activation Protein-alpha by Differential Degradomics and Proteomics
Hui Emma Zhang et al.
MOLECULAR & CELLULAR PROTEOMICS (2019)
A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21
Steven A. Kliewer et al.
CELL METABOLISM (2019)
Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes
Diana Barb et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output
Junling Liu et al.
EBIOMEDICINE (2019)
Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP)
An De Decker et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Fibroblast activation protein in liver fibrosis
Angelina J. Lay et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2019)
Liver Plays a Major Role in FGF-21 Mediated Glucose Homeostasis
Mingyao Liu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Fibroblast Growth Factor 21-Metabolic Role in Mice and Men
Harald Staiger et al.
ENDOCRINE REVIEWS (2017)
Changes in concentrations of circulating fibroblast activation protein alpha are associated with myocardial damage in patients with acute ST-elevation MI
Jochen Tillmanns et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans
Ricardo J. Samms et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
LPS infusion suppresses serum FGF21 levels in healthy adult volunteers
Esben S. Lauritzen et al.
ENDOCRINE CONNECTIONS (2017)
Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP)
Travis W. Bainbridge et al.
SCIENTIFIC REPORTS (2017)
FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms
Lucas BonDurant et al.
CELL METABOLISM (2017)
Circulating FGF21 proteolytic processing mediated by fibroblast activation protein
Eugene Y. Zhen et al.
BIOCHEMICAL JOURNAL (2016)
Expression Atlas update-an integrated database of gene and protein expression in humans, animals and plants
Robert Petryszak et al.
NUCLEIC ACIDS RESEARCH (2016)
Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus
Y. Hu et al.
DIABETES & METABOLISM (2016)
Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21
Diana Ronai Dunshee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Fibroblast activation protein (FAP) as a novel metabolic target
Miguel Angel Sanchez-Garrido et al.
MOLECULAR METABOLISM (2016)
Human FGF-21 Is a Substrate of Fibroblast Activation Protein
Andrew L. Coppage et al.
PLOS ONE (2016)
FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism
Yusuke Joki et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation
Xiaoqing Yan et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
FGF21 and cardiac physiopathology
Anna Planavila et al.
FRONTIERS IN ENDOCRINOLOGY (2015)
FGF21 Acts Centrally to Induce Sympathetic Nerve Activity, Energy Expenditure, and Weight Loss
Bryn M. Owen et al.
CELL METABOLISM (2014)
Serum Fibroblast Growth Factor-21 Levels Are Associated With Carotid Atherosclerosis Independent of Established Cardiovascular Risk Factors
Wing Sun Chow et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease
Yun Shen et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Circulating concentrations of fibroblast activation protein α in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA
Jochen Tillmanns et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities-the BEGAMI study
C. Hage et al.
JOURNAL OF INTERNAL MEDICINE (2013)
FGF21 regulates metabolism and circadian behavior by acting on the nervous system
Angie L. Bookout et al.
NATURE MEDICINE (2013)
Fibroblast growth factor 21 protects against cardiac hypertrophy in mice
A. Planavila et al.
NATURE COMMUNICATIONS (2013)
Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes
Camilla Hage et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2013)
Circulating Fibroblast Growth Factors as Metabolic Regulators-A Critical Appraisal
Bo Angelin et al.
CELL METABOLISM (2012)
Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques
So-Yeon An et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2012)
Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α
Fiona M. Keane et al.
FEBS JOURNAL (2011)
Fibroblast Growth Factor 21 Induces Glucose Transporter-1 Expression through Activation of the Serum Response Factor/Ets-Like Protein-1 in Adipocytes
Xuan Ge et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Jody Dushay et al.
GASTROENTEROLOGY (2010)
Serum Levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile
Zhuofeng Lin et al.
PLOS ONE (2010)
Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance
Alberto O. Chavez et al.
DIABETES CARE (2009)
Different Roles of N- and C-Termini in the Functional Activity of FGF21
Radmila Micanovic et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man
Cecilia Gaelman et al.
CELL METABOLISM (2008)
Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans
Xinmei Zhang et al.
DIABETES (2008)
Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys
Bumsup Lee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein
KN Lee et al.
BLOOD (2006)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
GA Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
FGF-21 as a novel metabolic regulator
A Kharitonenkov et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein α
K Aertgeerts et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Expression, purification, and kinetic characterization of full-length human fibroblast activation protein
SX Sun et al.
PROTEIN EXPRESSION AND PURIFICATION (2002)
Share Paper
